【众生药业:子公司一类创新药RAY1225注射液两项降糖III期临床试验获伦理批件】众生药业5月25日晚间公告,公司控股子公司广东众生睿创生物科技有限公司自主研发的一类创新多肽药物RAY1225注射液用于2型糖尿病患者的两项III期临床试验获得组长单位北京大学人民医院伦理审查批件,批准项目开展。RAY1225注射液是具有全球自主知识产权的创新结构多肽药物,具有GLP-1受体和GIP受体双重激动活性。

金融界
25 May
众生药业5月25日晚间公告,公司控股子公司广东众生睿创生物科技有限公司自主研发的一类创新多肽药物RAY1225注射液用于2型糖尿病患者的两项III期临床试验获得组长单位北京大学人民医院伦理审查批件,批准项目开展。RAY1225注射液是具有全球自主知识产权的创新结构多肽药物,具有GLP-1受体和GIP受体双重激动活性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10